Friday 25 May |
Hochschild Mining |
Ferrexpo |
Keywords Studios |
Lookers |
Informa |
Spectris |
ContourGlobal |
Old Mutual (re managed separation) |
Monday 28 May |
no events scheduled |
Tuesday 29 May |
Afarak group |
Belvoir Lettings |
Eddie Stobart Group |
Standard Life Aberdeen |
Oxford Biomedica |
Harworth Group |
Playtech (re acquisition of Snaitech) |
Wednesday 30 May |
AG Barr |
Bodycote |
Crudader Resources |
Royal Bank of Scotland Group |
Frenkel Topping Group |
Safestyle UK |
Fresnillo |
Thursday 31 May |
Brady |
Card Factory |
e-Therapeutics |
Faron Pharmaceuticals |
Porta Communications |
Total Produce |
Northbridge Industrial |
Sirius Minerals |
IN BRIEF: Faron research sheds light on Covid-linked mutations
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Publishes research expanding on analysis of a gene mutation in an interferon receptor that is linked to corticosteroid response and outcomes in acute respiratory distress syndrome and Covid-19 patients. Builds on Faron's findings from its phase III 'Interest' trial for Traumakine in ARDS patients. Traumakine is an investigational intravenous interferon beta-1a therapy.
Read more